Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hematology

Thalidomide maintenance in multiple myeloma

Thalidomide is frequently used in patients with newly diagnosed and relapsed multiple myeloma, but its role as maintenance therapy following autologous stem-cell transplantation has been an area of uncertainty. In this article we consider the efficacy of thalidomide maintenance therapy in multiple myeloma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Spencer, A. et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27, 1788–1793 (2009).

    Article  CAS  PubMed  Google Scholar 

  2. D'Amato, R. J., Loughman, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci.USA 91, 4082–4085 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Vacca, A. et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87, 503–508 (1994).

    Article  CAS  PubMed  Google Scholar 

  4. Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571 (1999).

    Article  CAS  PubMed  Google Scholar 

  5. Palumbo, A. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825–831 (2006).

    Article  CAS  PubMed  Google Scholar 

  6. Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P. R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431–436 (2006).

    Article  CAS  PubMed  Google Scholar 

  7. Stewart, A. K. et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin. Cancer Res. 10, 8170–8176 (2004).

    Article  CAS  PubMed  Google Scholar 

  8. Attal, M. et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108, 3289–3294 (2006).

    Article  CAS  PubMed  Google Scholar 

  9. Barlogie, B. et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 354, 1021–1030 (2006).

    Article  CAS  PubMed  Google Scholar 

  10. Morgan, G. J. et al. Maintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisation [abstract]. Blood (ASH Annual Meeting Abstracts) 112, 656 (2008).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jacob P. Laubach.

Ethics declarations

Competing interests

P. Richardson is an Advisory Board member for Celgene and Millenium. K Anderson is a Consultant and receives research/grant support from Celgene and Millenium.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laubach, J., Richardson, P. & Anderson, K. Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol 6, 565–566 (2009). https://doi.org/10.1038/nrclinonc.2009.131

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.131

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing